- Home
- GAM vs ARDX Comparison
GAM vs ARDX Comparison
Compare GAM & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAM
- ARDX
- Stock Information
- Founded
- GAM 1927
- ARDX 2007
- Country
- GAM United States
- ARDX United States
- Employees
- GAM N/A
- ARDX N/A
- Industry
- GAM Investment Managers
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- GAM Finance
- ARDX Health Care
- Exchange
- GAM Nasdaq
- ARDX Nasdaq
- Market Cap
- GAM 1.2B
- ARDX 1.2B
- IPO Year
- GAM N/A
- ARDX 2014
- Fundamental
- Price
- GAM $52.48
- ARDX $5.49
- Analyst Decision
- GAM
- ARDX Buy
- Analyst Count
- GAM 0
- ARDX 7
- Target Price
- GAM N/A
- ARDX $9.42
- AVG Volume (30 Days)
- GAM 20.1K
- ARDX 5.1M
- Earning Date
- GAM 01-01-0001
- ARDX 02-20-2025
- Dividend Yield
- GAM 5.74%
- ARDX N/A
- EPS Growth
- GAM N/A
- ARDX N/A
- EPS
- GAM 11.67
- ARDX N/A
- Revenue
- GAM N/A
- ARDX $251,849,000.00
- Revenue This Year
- GAM N/A
- ARDX $169.09
- Revenue Next Year
- GAM N/A
- ARDX $15.06
- P/E Ratio
- GAM $3.95
- ARDX N/A
- Revenue Growth
- GAM N/A
- ARDX 87.57
- 52 Week Low
- GAM $37.32
- ARDX $4.32
- 52 Week High
- GAM $46.48
- ARDX $10.13
- Technical
- Relative Strength Index (RSI)
- GAM 54.51
- ARDX 54.79
- Support Level
- GAM $52.01
- ARDX $4.85
- Resistance Level
- GAM $53.88
- ARDX $5.80
- Average True Range (ATR)
- GAM 0.66
- ARDX 0.40
- MACD
- GAM 0.13
- ARDX 0.04
- Stochastic Oscillator
- GAM 59.67
- ARDX 52.46
About GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.